Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics, the biotechnology company focusing on allergy vaccines, has introduced a new long-term incentive plan (LTIP) to align the interests of its key management with those of shareholders, incentivizing long-term value creation. Share options have been granted to senior executives, including the CEO and CFO, with vesting contingent on performance and share price criteria over a three-year period. Additionally, the company has announced a change in the name of its Nominated Adviser and Broker to Panmure Liberum Limited.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
